Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: J Pain Symptom Manage. 2019 Jul 16;58(5):774–783. doi: 10.1016/j.jpainsymman.2019.07.008

Priority Symptoms, Causes, and Self-Management Strategies Reported by AYAs with Cancer

Lauri A Linder 1, Kristin Stegenga 2, Jeanne Erickson 3, Suzanne Ameringer 4, Amy R Newman 5, Yin-Shun Chiu 6, Catherine Fiona Macpherson 7
PMCID: PMC6823142  NIHMSID: NIHMS1534821  PMID: 31319104

Abstract

Context:

Cancer and symptom experiences of adolescents and young adults (AYAs) with cancer can be highly variable, creating challenges for clinicians and researchers who seek to optimize AYAs’ health outcomes. Understanding the heuristics AYAs use to designate priority symptoms can provide insight into the meaning they assign to their symptoms and self-management behaviors.

Objectives:

This study described the frequency and characteristics of priority symptoms. It qualitatively explored reasons for a symptom’s designation as a priority symptom, perceived causes of priority symptoms, and strategies AYAs use to manage priority symptoms.

Methods:

Participants in this single group, longitudinal study reported symptoms using a heuristics-based symptom reporting tool, the Computerized Symptom Capture Tool, at two scheduled visits for chemotherapy. AYAs designated priority symptoms and responded to two short answer questions: What makes this a priority symptom? and What do you do to make it better?

Results:

Eighty-six AYAs, 15-29 years of age (median 19 years), identified 189 priority symptoms. Priority symptoms were of greater severity (t=3.43; p< .01) and distress (t=4.02; p< .01) compared with non-priority symptoms. Lack of energy, nausea, difficulty sleeping, and pain comprised 39% of priority symptoms. Reasons for priority designation included the impact of the symptom and the attributes of the symptom. Categories of self-management strategies included “Physical Care Strategies,” “Things I take (or not),” and “Psychosocial Care Strategies.”

Conclusion:

Supporting AYAs to identify their priority symptoms may facilitate a more personalized approach to care. Seeking the patient’s perspective regarding priority symptoms could enhance patient-clinician collaboration in symptom management.

Keywords: symptoms, symptom self-management, adolescents and young adults, cancer, technology

Introduction

The National Cancer Institute (NCI) defines adolescents and young adults (AYAs) as patients between the ages of 15 and 39 years based on types of cancers AYAs are more likely to acquire and evidence that indicates some of these cancers may have unique genetic and biological characteristics.1 During the transition from adolescent, to emerging adult, to young adult, AYAs’ attainment of physiological maturity, independence, and assumption of traditional adult roles in society are multidimensional and very individual.2 As a result, AYAs’ cancer and symptom experiences are highly variable and dynamic, creating challenges for clinicians and researchers who seek to optimize AYAs’ health outcomes.

These developmental factors have important implications for the health-related behaviors of AYAs with cancer, including how they interpret their symptoms and make self-management decisions. The heuristics, or mental rules, AYAs use to interpret their illness and symptoms are based on cognitive processing, prior experiences, cultural beliefs, and social comparisons.3 Understanding AYAs’ symptom heuristics can provide insight into their self-management behaviors and the meaning they assign to their symptoms.

To partner with AYAs in managing their symptoms, providers need a consistent approach to elicit the symptoms AYAs are experiencing, including those which are of priority to them. Standard approaches to symptom assessment with AYAs with cancer do not exist. Measures and indices of symptoms and symptom burden have been developed for adults with varying types of cancer.49 The development of many of these measures included patient perspectives around the most bothersome and most important symptoms. While the measures were developed around the concept of priority symptoms, many of these measures are intended to provide an overall assessment, or score, of the patient’s overall symptom burden, health-related quality of life, and response to treatment. While patient perceptions and priorities in symptom assessment and management are encouraged,10,11 reports soliciting patient priorities at the individual level within a clinical encounter are lacking.

A recent study asked women with recurrent ovarian cancer to identify the top three symptoms for which they would like to get better control, i.e., what are their priority symptoms.12 Provider documentation and management of priority symptoms were then examined. While the top four priority symptoms (fatigue, peripheral neuropathy, sleep disturbances, and pain) reported by women were also most frequently documented by providers, 53% of all priority symptoms were not documented by the provider. This lack of documentation suggests that providers may not specifically ask patients to assign priority to their symptoms.

Having AYAs identify their own priority symptoms, the symptoms that are most important to them, is consistent with the concept of personalized healthcare. Personalized medicine is defined by the National Institutes of Health as “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.”13 Personalized healthcare is the broader term and is defined as “the tailoring of medical management and patient care to the individual characteristics of each patient,”14 and includes, for example, identification of patients’ priorities to be used as guiding principles for collaborative care.15 In addition to medical management, the concept of personalized healthcare includes the self-management of symptoms. Thus, symptom self-management calls for a patient-centered approach, demonstrating the need for patients to be able to identify and voice their priority symptoms. The desire for this individualized approach has been expressed by individuals with cancer in other symptom management studies.16 The Computerized Symptom Capture Tool (C-SCAT) developed by the investigators17 allows AYAs to efficiently and precisely identify not only all symptoms they are experiencing, but more importantly, symptoms that are priorities to them.

Purpose

This study explored priority symptoms identified by AYAs receiving chemotherapy and the heuristics they use in relation to those symptoms. Specifically, this study described and compared the frequency and characteristics of priority and non-priority symptoms. The study also qualitatively explored reasons a given symptom was identified as a priority symptom, perceived causes of priority symptoms, and strategies AYAs use to manage priority symptoms.

Methods

Design

This study used a single group, longitudinal, mixed methods design in which participants reported symptoms at two scheduled visits for receipt of chemotherapy. Participants used the C-SCAT, a heuristics-based symptom reporting tool, to relate their symptom experiences during the previous 24 hours.

Sample and Setting

Eligible participants were AYAs 15-29 years of age receiving myelosuppressive chemotherapy as treatment for cancer. An age range narrower than that designated by the NCI was selected to recruit a study sample more likely to have similar life experiences compared with AYAs 30 years of age and older.18,19 Participants were required to have completed at least one cycle of chemotherapy and anticipated to receive at least two additional cycles in order to be able to complete all study visits. Additional inclusion criteria were the ability to read, speak, and understand English and be physically and cognitively capable of completing study procedures. Participants were recruited from five academic medical centers in the Southeast, Midwest, Intermountain West, and Southwest United States treating AYAs with cancer.

Study Measure

The study measure was the C-SCAT, an investigator-developed, heuristic-based symptom reporting tool that is administered via a tablet computer.17 Users create a graphical image of their symptom experiences by selecting symptoms from a menu of 32 symptoms included in the Memorial Symptom Assessment Scale (MSAS)20 that they have experienced during the previous 24 hours. They identify the perceived cause of each symptom and rate each symptom’s severity and distress using the scales from the MSAS. Severity is measured on a 1-4 scale with 1=slight to 4=very severe. Distress is measured on a 0-4 scale with 0=none to 4=very much, recognizing that the presence of a symptom may or may not be perceived as distressing. Users then identify temporal and causal relationships between symptoms and have the option to designate clusters, or groups, of symptoms that they perceive to occur together. Finally, users identify priority symptoms within each cluster, “Tap the most important symptom in each group. If you did not draw any groups, tap the symptom that is most important to you”. As users designate priority symptoms, they are asked: 1) What makes this a priority symptom? and 2) What do you do to make it better? Output includes a final image (Figure 1) and an .xml file containing text-based data.

Figure 1:

Figure 1:

C-SCAT Image from a 16-year-old male with acute lymphoblastic leukemia The participant identified a total of nine symptoms. Green lines between symptoms indicate a perceived relationship between the symptoms. Blue arrows indicate perceived causal relationships. Five symptoms were grouped into two clusters, designated and named by the AYA, “Eating and Energy” and “Fatigue.” Priority symptoms, those perceived by the AYA as most important within each cluster, are designated with red ribbons and are “weight loss” and “lack of energy.” The priority cluster, or group of symptoms, perceived as being the most important group, “Fatigue,” is designated with a blue ribbon.

Study Procedures

Institutional review board approval was granted from each study site. Study team members routinely screened clinic and inpatient admission schedules for potentially eligible participants. Among AYAs who met preliminary screening criteria, reasons for ineligibility were most frequently related to the patient’s treatment plan, specifically, uncertainty about the exact number of additional chemotherapy cycles. Written assent and written parental permission were obtained for patients 15 to 17 years of age. Patients 18 years of age and older provided written informed consent. At the enrollment visit, AYAs provided baseline demographic information about themselves using Research Electronic Data Capture (REDCap).21 Clinical data, including diagnosis, months since initial diagnosis, and disease status were identified through medical record review.

A study team member met with the AYA prior to each of the next two scheduled visits for chemotherapy administration (Visits 1 and 2) to review study procedures and be available as a resource while AYAs completed the C-SCAT. AYAs received a copy of their C-SCAT-generated image to review with their provider. They also received a gift card after each visit.

Data Management and Analysis

Quantitative data.

Demographic data from REDCap and quantitative C-SCAT-generated data were imported into SPSS files for analyses. Descriptive statistics and measures of central tendency characterized the study sample and the frequencies of symptoms, priority symptoms, and their associated characteristics. Independent sample t-tests compared the severity and associated distress of priority versus non-priority symptoms. Chi-square analyses compared differences in frequencies of categories of AYAs’ responses.

Qualitative data.

Qualitative data from C-SCAT files were organized into Excel files to support coding procedures. Qualitative content analysis procedures22,23 were used to analyze AYAs’ reported: 1) reasons for designating a given symptom as a priority symptom, 2) perceived causes of the priority symptom, and 3) strategies used to alleviate the symptom. Authors reviewed responses across questions to gain a sense of the data as a whole and perspective of how responses to one question may have also been reflected in responses to the other two questions. Each question was then analyzed independently with individual responses treated as the unit of analysis.22,23 Four investigators (LL, CM, AN, KS) reviewed data independently and assigned preliminary codes. They then met together to review codes. Discrepancies were infrequent and were resolved through discussion to reach consensus for all coded responses. Codes were further organized into categories and subcategories.

Results

Participants

Eighty-eight AYAs enrolled in the study, and 86 completed at least one C-SCAT visit. Recruitment rates averaged 76% across sites. The most frequent reason for declining was lack of interest. Reasons for withdrawal included completion of therapy before C-SCAT visits could be completed and a parent’s decision to withdraw his son after further reviewing the parental permission and participant assent documents. Participants were a median of 19 years of age (range 15-29), and a median of 5 months (range 1-48) since initial diagnosis. Demographic characteristics of AYAs who completed at least one C-SCAT visit are included in Table 1.

Table 1.

Participant Characteristics

Characteristic N % Mean (SD) Median Range
Gender
 Male 45 52.3
 Female 41 47.7
Age (years) 21 (5.0) 19 15-29
Age Group
 Adolescent (15-18 years) 40 46.5
 Young Adult (19-29 years) 46 53.5
Race
 White 61 70.9
 Other/more than one race 12 14
 African-American 10 11.6
 Native American/Alaska Native 2 2.3
 Asian 1 1.2
Ethnicity
 Non-Hispanic 67 77.9
 Hispanic 19 22.1
Diagnosis
 Acute lymphoblastic leukemia 27 31.3
 Hodgkin lymphoma 13 15.1
 Sarcoma 10 11.6
 Brain tumor 8 9.3
 Breast cancer 7 8.1
 Non-Hodgkin lymphoma 7 8.1
 Acute promyelocytic leukemia 4 4.7
 Other 4 4.7
 Acute myelogenous leukemia 3 3.5
 Chronic myelogenous leukemia 3 3.5
Disease status
 Initial diagnosis 82 95.3
 Relapsed/refractory disease 3 3.5
 Secondary 1 1.2
Months since initial diagnosis 11.7 (13.1) 5 1-48

Symptoms

At Visit 1, AYAs reported a total of 468 symptoms (mean=5.44; SD=4; range = 0-15). Eighty-nine of these symptoms were designated as priority symptoms (median=1; range=0-3). At Visit 2, AYAs reported a total of 377 symptoms (mean 4.44; SD=3.8; range 0-18). Eighty of these symptoms were designated as priority symptoms (median=1; range=0-3). Table 2 reports the most frequently reported symptoms.

Table 2.

Most Frequently Reported Symptoms Across Visits

Symptom n
Lack of Energy 71
Feeling Drowsy 53
Difficulty Sleeping 52
Pain 51
Nausea 48
Hair Loss 46
Feeling Irritable 38
Changes in How Food Tastes 37
Lack of Appetite 33
Tingling in Hands/Feet 33

Twenty-nine of the 32 symptoms included in the C-SCAT were designated as a priority symptom at least once. Priority symptoms were reported as more severe (t=3.43; p< .01) and distressing (t=4.02; p< .01) compared with non-priority symptoms. Priority symptoms were of moderate or greater severity on 83% of occasions and of somewhat or greater distress on 68% of occasions. Figure 3 summarizes the 11 most frequent priority symptoms across visits along with the occasions each priority symptom was rated as of moderate or greater severity and distress. Three symptoms were never named as priority symptoms: dry mouth, problems with urination, and swelling in arms and legs.

Lack of energy, nausea, difficulty sleeping, and pain comprised 39% of all reported priority symptoms. For these four symptoms, severity and distress did not differ based on priority designation (Table 3). These symptoms were also of moderate or greater severity on more than 80% of reported occasions regardless of priority designation.

Table 3.

Comparison of Symptom Severity and Distress for Four Most Frequent Priority Symptoms

Mean Severity (SD)* Mean Distress (SD)**

Priority Non-priority Priority Non-Priority
Lack of energy 2.3 (0.7) 2.1 (0.7) 1.8 (0.8) 1.9 (1.2)
Nausea 2.2 (0.71) 2.2 (0.8) 2.4 (1.3) 2.0 (1.1)
Difficulty sleeping 2.2 (0.8) 2.0 (0.7) 2.2 (0.9) 1.9 (1.2)
Pain 2.6 (1.0) 2.3 (0.7) 2.7 (0.8) 2.4 (1.2)
*

Differences in severity not statistically significant based on priority/non-priority designation

**

Differences in distress not statistically significant based on priority/non-priority designation

Reasons for Designating a Symptom as Priority

Participants provided 153 responses to the question, “What makes this a priority symptom?” These responses were organized into 158 codes that were organized into three categories (Impact of Symptoms, Attributes of Symptoms, Don’t Know) and seven subcategories (Table 4). Definitions of categories and subcategories arose from the AYAs’ responses. Post-hoc comparisons indicated that AYAs’ reasons for designating a symptom as priority did not differ based on the visit (Visit 1 versus Visit 2) (X2=2.66; p=.85). Reasons for designating a symptom as priority also did not differ based on whether the symptom was one of the four most frequently reported priority symptoms versus the other priority symptoms (X2=8.94; p=.18).

Table 4.

Categories and Subcategories of Reasons for a Symptom’s Designation as Priority

Categories and Subcategories Frequency (%) Example
Impact of the Symptom 101 (63.9)

 Physical impact 36 “Nausea makes me feel sick and it decreases my appetite” (Nausea, 16 y/o F with Hodgkin lymphoma [HL])
“It makes the rest of my body weaker” (Lack of energy, 19 y/o M with rhabdomyosarcoma [RMS])
“It makes me feel bloated and nauseous” (Constipation, 19 y/o M with RMS)
 Well-being 34 “I need sleep and energy to get better” (Difficulty sleeping, 15 y/o M with acute lymphoblastic leukemia [ALL])
“Interferes with interpersonal interactions, not as even-tempered as usual” (Feeling irritable, 29 y/o F with breast cancer)
 Functional status 16 “Because I can’t do basic daily activities such as cooking” (Lack of energy, 28 y/o F with breast cancer)
“I need to think clearly, focus, and be concentrated in day-to-day life” (Difficulty concentrating, 16 y/o M with ALL)
 Emotional impact 15 “Anxious about appointments” (Difficulty sleeping, 29 y/o F with metastatic adenocarcinoma)
“This was my biggest fear” (Hair loss, 23 y/o M with ALL)

Attributes of the Symptom 56 (35.4)

 Severity/Distress 34 “It makes me feel the worst” (Nausea and constipation, 17 y/o F with HL)
“Pain is the most noticeable” (Pain, 23 y/o F with non-Hodgkin lymphoma [NHL])
“It bothers me the most” (Feeling bloated, 17 y/o F with HL)
 Causes the others 11 “Causes the rest of the symptoms” (Difficulty sleeping, 29 y/o F with ALL)
“I believe it leads to the rest” (Worrying, 28 y/o F with breast cancer)
“It causes the other symptoms” (Changes in how food tastes, 16 y/o F with sarcoma)
 Temporality 11 “Most prevalent” (Feeling bloated and lack of energy, 24 y/o male with HL)
“Constant symptom” (Vomiting, 25 y/o F with acute promyelocytic leukemia)
“I have felt this during the whole cancer process” (Feeling sad, 26 y/o F with NHL)

Don’t Know 1 (1.0)

The Impact of Symptoms category (n=101) included four subcategories. Physical impact (n=36) was most frequently named and reflected the immediate physical consequences of the symptom such as, “If nauseous then that causes me to throw up,” (15-year-old male with acute lymphoblastic leukemia [ALL]). Well-being (n=34) encompassed AYAs’ awareness of what they perceived to be healthy behaviors and how the given symptom affected these behaviors, “I need good sleep,” (29-year-old female with adenocarcinoma).

Priority symptoms adversely impacted AYAs’ functional status (n=16), that is, their ability to perform expected day-to-day roles, such as “Makes doing daily activities difficult,” (26-year-old male with ALL). The emotional impact of the symptom (n=15), such as, “I miss my hair,” (23-year-old male with ALL) also resulted in its designation as a priority symptom.

The Attributes of Symptoms category (n=56) contained three subcategories. The severity and/or distress associated with a given symptom (n=34), as in “It bothers me the most,” (17-year-old female with Hodgkin lymphoma), was the most frequently reported attribute. Other named attributes of a symptom that resulted in its designation as a priority symptom included its perception as a symptom that caused other symptoms (n=11), “I believe it leads to [the] rest,” (28-year-old female with breast cancer) or its temporality, that is, its persistence or frequency over time (n=11), “It happens every day,” (26-year-old female with a brain tumor).

Perceived Causes of Priority Symptoms

AYAs provided 123 responses to the question, “What do you think caused it [the priority symptom]? These responses were organized into 135 codes that were further organized into four categories: chemotherapy/treatment (n=91), other health conditions (n=22), psychosocial factors (n=11), and don’t know (Table 5). Post-hoc comparison of frequencies of perceived causes did not differ based on the visit (X2=4.64; p=.20) or whether a symptom was one of the four most frequently reported priority symptoms versus the other priority symptoms (X2=1.40; p=.71).

Table 5.

Categories and Subcategories of Perceived Causes of Priority Symptoms

Categories/Subcategories Frequency (%) Example
Chemotherapy/Treatment 91 (67.4)
 Medications 71 “Chemo” or “chemotherapy” (multiple patients with various diagnoses)
“My medicine” (Lack of energy, 17 y/o M with brain cancer)
“Meranol” (Difficulty sleeping, 15 y/o M with acute lymphoblastic leukemia [ALL])
 Cancer and treatment-related symptoms 11 “Feet pain possibly caused by vincristine” (Pain, 16 y/o F with non-Hodgkin lymphoma [NHL])
“Hair loss” (Don’t look like myself, 16 y/o F with NHL)
 Experience of going through treatment 9 “Tough scheduling appointments every day… ” (Difficulty sleeping, 19 y/o M with rhabdomyosarcoma [RMS])
“Surgery… ” (Tingling in hands, 20 y/o M with RMS)
Other Physical Condition 22 (16.3) “Dizziness” (Nausea, 17 y/o M with NHL)
“Back problems” (Pain, 28 y/o F with ALL)
Psychosocial Cause 11 (8.1) “Anxiety” (Nausea, 23 y/o F with NHL)
“Mixed emotions from chemotherapy” (Worrying, 16 y/o F with NHL)
Don’t Know 11 (8.1)

The medications that AYAs were receiving as part of their cancer treatment, such as “chemo,” “vincristine,” and “going off prednisone,” predominated as perceived causes. AYAs also identified other cancer-related symptoms as causing priority symptoms such as “lack of sleep” as causing fatigue and “lack of appetite” causing weight loss. The larger cancer and treatment experience was also reflected in perceived causes such as “The whole process I have to go through” and “Tough scheduling for appointments everyday.”

Although less frequently reported, AYAs’ responses included other health conditions that were not specific to their cancer. These included perceived causes such as “allergies,” “Crohn’s disease,” and “back problems.” Psychosocial factors perceived as causes of priority symptoms included “stress,” “anxiety,” “scary thoughts,” and “circumstances.” Eleven responses included “don’t know” as the perceived cause.

Strategies for Self-Managing Priority Symptoms

AYAs provided 140 responses to the question “What do you do to make it [the priority symptom] better? These responses were organized into 174 codes that were further organized into five categories: “Physical Care Strategies,” “Something I Take (or not),” “Psychosocial care Strategies,” “Nothing,” and “Don’t Know” (Table 6). Post-hoc comparison of frequencies of self-management strategies did not differ based on the visit (X2=2.39; p=.79). Self-management strategy frequencies differed based on whether a symptom was one of the four most frequently reported priority symptoms (X2=19.44; p <.01). AYAs more frequently reported taking medications (or not) to manage nausea, pain, and difficulty sleeping. Psychosocial strategies were more frequently reported to manage the less prevalent priority symptoms, particularly those with a psychological component, such as feeling irritable, worrying, and feeling nervous.

Table 6.

Categories of Strategies for Self-Managing Priority Symptoms

Categories Frequency (%) Example
Physical Care Strategies 101 (59.4) “Try to relax or sit down” (Pain, 16 y/o F with non-Hodgkin lymphoma [NHL])
“Ice, rest, massage, acupuncture” (Pain, 29 y/o F with acute lymphoblastic leukemia [ALL])
“Just eat the foods I can” (Changes in how food tastes, 16 y/o F with sarcoma)
“Shorter activity or more recovery, take it easier when exercising” (Shortness of breath, 29 y/o F with breast cancer)
Things I Take (or not) 42 (24.7) “Take medicine” (Nausea, 15 y/o M with ALL)
“Sometimes not taking my pills” (Difficulty sleeping, 19 y/o M with ALL)
“Take Miralax or another laxative” (Constipation, 17 y/o F with NHL)
Psychosocial Care Strategies 19 (11.2) “Distract myself with music” (Worrying, 28 y/o F with breast cancer)
“Try to relax and think” (Difficulty concentrating, 16 y/o M with ALL)
“Reframe angry thoughts” (Feeling irritable, 29 y/o female with breast cancer)
Nothing 10 (4.1) “Nothing”
“Can’t do much right now” (Don’t look like myself, 17 y/o F with NHL)
Don’t Know 2 (1.0) “No idea” (Difficulty concentrating, 16 y/o M with rhabdomyosarcoma)

Physical care strategies were most frequently reported (n=101) and reflected a variety of efforts including managing rest and activity, adjusting eating habits, and the use of integrative therapies. “Something I take (or not)” (n=42) included both prescribed and over-the-counter medications, particularly for managing pain and nausea. Responses also reflected AYAs’ choices in relation to their medications. These choices included intentional nonadherence to prescribed treatment-related medications, for example one AYA reported, “Sometimes not taking my medicine,” to alleviate difficulty sleeping. Another AYA related how she made choices with a prescribed pain medication in an effort to alleviate constipation, “Reduce Oxy intake and take miralax.”

Psychosocial care strategies (n=19) included both intrapersonal efforts such as, “Reframe angry thoughts,” and interpersonal strategies, “Being with family.” Ten responses indicated a lack of an effective self-management strategy either as “nothing” or ineffective past efforts such as, “I’ve try some thing (sic) but nothing seems to work.”

Discussion

This study explored symptoms reported by AYAs with cancer prior to receiving a cycle of chemotherapy and specifically sought insight into the symptoms the AYAs identified as ‘priority symptoms.’ Consistent with previous reports, AYAs reported multiple symptoms during treatment, with some participants reporting over 15 concurrent symptoms.2426 This high number is especially concerning because symptom self-reports were collected before the administration of chemotherapy, a time when the presence of symptoms is expected to be low.

Fatigue, difficulty sleeping, nausea, and pain were the most frequent priority symptoms and among the most frequently reported symptoms overall. Given that these symptoms contribute to a higher symptom burden2729 and that they were of moderate or greater severity more than 80% of reported occasions, a report of these symptoms warrants clinician attention regardless of priority designation.

Not expected was the finding that all but three symptoms included in the C-SCAT were identified by AYAs as priority symptoms at least once. These symptoms included other physical symptoms, such as lack of appetite, hair loss, and tingling in hands and feet, as well as psychological symptoms and responses, such as worry and feeling irritable. Further, this research indicates that the priority symptoms AYAs identified were not always apparent.24 For example, one cluster of symptoms that an AYA identified included dizziness, dry mouth, and feeling drowsy. The priority symptom was feeling drowsy, which is not obvious and would require further assessment. Although symptoms such as hair loss may not have a present remedy, acknowledging their presence and significance to the AYA may be a “solution” in and of itself. Additionally, the clinician could recommend resources to help alleviate distress associated with the symptom.

Study findings also emphasize the relevance of inquiring about the reason for a symptom’s designation of priority, a feature lacking in most measures that include ratings of severity and distress.30,31 Most of the reasons for symptoms’ priority designations were not their severity or distress but rather their effects on the body. These effects included function, as well as general physical and emotional well-being.

Consistent with results from the initial study using the C-SCAT,24 priority symptoms were most frequently ascribed to cancer and cancer treatment. These findings also align with reports examining symptom experiences of adults with cancer, who largely associate their symptoms with cancer-related morbidity and treatment.32 AYAs’ frequent attribution of their priority symptoms to cancer and cancer treatment underscores the need to engage and encourage them to discuss their symptom experiences. If AYAs believe their symptoms are expected or unavoidable aspects of the cancer experience, they may hesitate to address them with providers and struggle to manage them independently. As AYAs consider symptoms within the context of their illness and the medications they are required to take, they may decide not to take medications, including oral chemotherapy or other prescribed medications, as a means to manage symptoms.33,34 Viewing nonadherence behaviors in the context of symptom self-management rather than regarding them as irrational acts of noncompliance may support clinicians in gaining a greater understanding of the AYA’s perspective. Exploring with AYAs not only the symptoms they are experiencing, but also what they believe is causing them, is an integral part of patient-centered symptom assessment and management and supporting patients in symptom self-management.

AYAs’ self-management strategies for priority symptoms were also consistent with those reported in the initial study using the C-SCAT35 and reflect AYAs’ individual preferences and approaches. Although medications were frequently reported, particularly for nausea, pain, and difficulty sleeping, the majority of strategies were ones that do not require a prescription. Many also align with evidence-based guidelines such as balancing activity and rest. Strategies also reflected some AYAs’ interest in incorporating integrative therapies for symptom self-management. Clinicians need to be aware of the range of AYAs’ symptom self-management strategies and to ask about perceived efficacy.

Study results suggest value in clinicians using a structured approach to symptom assessment and management and adds to the literature addressing the role of electronically-administered patient-reported outcome measures.36,37 These resources may improve efficiency with regards to collecting patient-reported measures to support a more patient-centric approach to care. Adopting a patient-centered approach that acknowledges the priority symptom/s of the AYA, rather than the clinician, as well as the AYA’s current self-management strategies and their perceived efficacy, supports a more personalized approach to symptom assessment, and may enhance patient-clinician collaboration in symptom management.

A limitation of this study is the manner in which AYAs designated priority symptoms. The C-SCAT allowed users to designate only one priority symptom within each identified cluster. As a consequence, priority symptoms may not have been based on rank order. Users who reported more than one symptom but did not identify a cluster, could designate only one priority symptom.

Although the C-SCAT has not undergone psychometric evaluation, it includes symptoms and rating scales included in the MSAS, a tool with established reliability and validity.20 Additionally, the C-SCAT’s larger focus, is not to measure a distinct construct, but rather to identify the individual AYA’s distinct perspective of his/her symptom experience including perceived relationships between symptoms.

This study demonstrates the C-SCAT’s potential to support a personalized approach to symptom management through the identification of priority symptoms and the heuristics AYAs use in designating priority symptoms. Emphasizing priority symptoms will guide clinicians to a greater understanding of the negative impact of symptoms on AYAs’ daily lives and foster more meaningful personalized interventions to enhance their quality of life. Future studies should evaluate the efficacy of the C-SCAT to facilitate improved symptom outcomes.

Figure 2:

Figure 2:

Summary of most frequent priority symptoms and frequency with which these symptoms were of moderate or greater severity and somewhat or greater distress

Disclosures and Acknowledgements

None of the authors has conflicts of interest to disclose.

Funding sources:

  • University of Utah Vice President’s Pilot Award

  • St. Baldrick’s Foundation

  • Clinical and Translational Science Institute of Southeast Wisconsin

  • Advancing a Healthier Wisconsin Foundation

  • National Institute of Nursing Research of the National Institutes of Health, T32NR013456

  • National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR00105

  • CTSA at Virginia Commonwealth University, UL1TR002649

  • CTSA at Medical College of Wisconsin, UL1TR001436

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Contributor Information

Lauri A. Linder, University of Utah & Primary Children’s Hospital, Salt Lake City, UT; USA.

Kristin Stegenga, Children’s Mercy Hospital, Kansas City, MO; USA.

Jeanne Erickson, University of Wisconsin, Milwaukee, Milwaukee, WI; USA.

Suzanne Ameringer, Virginia Commonwealth University, Richmond, VA; USA.

Amy R. Newman, University of Utah, Salt Lake City, UT; USA.

Yin-Shun Chiu, University of Utah, Salt Lake City, UT; USA.

Catherine Fiona Macpherson, Seattle Children’s Hospital, Seattle, WA; USA.

References

  • 1.National Cancer Institute. Adolescents and young adults with cancer. 2018. Available from: https://www.cancer.gov/types/aya Accessed April 16, 2019.
  • 2.Arnett JJ. Conceptions of the transition to adulthood: Perspective from adolescence through midlife. J Adult Devel 2001;8:133–143. [Google Scholar]
  • 3.Leventhal H, Weinman J, Leventhal EA, Phillips LA. Health psychology: The search for pathways between behavior and health. Annu Rev Psychol 2008;59:477–505. [DOI] [PubMed] [Google Scholar]
  • 4.Cella D, Paul D, Yount S, et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 2003;21:526–535. 10.1081/CNV-120022366 [DOI] [PubMed] [Google Scholar]
  • 5.Galipeau N, Klooster B, Krohe M . Understanding key symptoms, side effects, and impacts of HR+/HER2-advanced breast cancer: Qualitative study findings. J Patient Rep Outcomes 2019;3:10 10.1186/s41687-019-0098-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Jensen SE, Rosenbloom SK, Beaumont JL, et al. A new index of priority symptoms in advanced ovarian cancer. Gynecol Oncol 2011;120:214–219. 10.1016/jygyno.2010.09.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Garcia SF, Rosenbloom SK, Beaumont JL, et al. Priority symptoms in advanced breast cancer: Development and initial validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16). Value Health 2012;15:183–190. 10.1016/j.val.2011.08.1739 [DOI] [PubMed] [Google Scholar]
  • 8.Lai JS, Jensen SE, Beaumont JL, et al. Development of a symptom index for patients with primary brain tumors. Value Health 2014;17:62–69. 10.1016/j.val.2013.11.006 [DOI] [PubMed] [Google Scholar]
  • 9.Victorson DE, Beaumont JL, Rosenbloom SK, Shevrin D, Cella D Efficient assessment of the most important symptoms in advanced prostate cancer: The NCCN/FACT-P Symptom Index. Psychooncology 2011;20:977–983. 10.1002/pon.1817 [DOI] [PubMed] [Google Scholar]
  • 10.Dong ST, Butow PN, Agar M, et al. Clinicians’ perspectives on managing symptom clusters in advanced cancer: A semistructured interview study. J Pain Symptom Manage 2016;51:706–717. 10.1016/jpainsymman.2015.11.021 [DOI] [PubMed] [Google Scholar]
  • 11.Stöomgren AS, Sjogren P, Goldschmidt D, et al. Symptom priority and course of symptomatology in specialized palliative care. J Pain Symptom Manage 2006;31: 199–206. 10.1016/j.jpainsymman.2005.07.007 [DOI] [PubMed] [Google Scholar]
  • 12.Hay CM, Courtney-Brooks M, Lefkowits C, et al. Symptom management in women with recurrent ovarian cancer: Do patients and clinicians agree on what symptoms are most important? Gynecol Oncol 2016;143:367–370. 10.1016/jygyno.2016.08.235 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.U.S. National Library of Medicine. What is precision medicine? Available from: https://ghr.nlm.nih.gov/primer/precisionmedicine/definition Accessed March 8, 2019
  • 14.Teng K, Eng C, Hess C, et al. Building an Innovative Model for Personalized Healthcare. Cleve Clin J Med 2012;79:S1–9. [DOI] [PubMed] [Google Scholar]
  • 15.Evers AW, Gieler U, Hasenbring MI, van Middendorp H. Incorporationg biopsychosocial characteristics into personalized healthcare: A clinical approach. Psychother and Psychosom 2014;83:148–157. [DOI] [PubMed] [Google Scholar]
  • 16.Heidrich SM, Brown RL, Egan JJ, Perez OA, Yeom H, & Ward SE (2009). An Individualized Representational Intervention to Improve Symptom Management (IRIS) in Older Breast Cancer Survivors: Three Pilot Studies. Oncology Nursing Forum, 36, E133–143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Macpherson CF, Linder LA, Ameringer S, et al. Feasibility and acceptability of an iPad application to explore symptom clusters in adolescents and young adults with cancer. Pediatr Blood Cancer 2014;61:1996–2003. [DOI] [PubMed] [Google Scholar]
  • 18.Arnett JJ. A theory of development from the late teens through twenties. Am Psychol 2000;55:469–480 [PubMed] [Google Scholar]
  • 19.National Cancer Institute. Adolescents and Young Adults with Cancer. 2018. Available from: https://www.cancer.gov/types/aya Accessed June 19, 2019.
  • 20.Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994;30A:1326–1336. [DOI] [PubMed] [Google Scholar]
  • 21.Harris PA, Taylor R, Thielke R, et al. Research Electronic Data Capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Elo S, Kyngas H. The qualitative content analysis process. J Adv Nurs 2008;62:107–115. [DOI] [PubMed] [Google Scholar]
  • 23.Krippendorff K Content analysis: An introduction to its methodology (4th ed). Thousand Oaks, CA: Sage; 2019. [Google Scholar]
  • 24.Ameringer S, Erickson JM, Macpherson CF, Stegenga K, Linder LA. Symptoms and symptom clusters identified by adolescents and young adults with cancer using a symptom heuristics app. Res Nurs Health, 2015;38:436–448. [DOI] [PubMed] [Google Scholar]
  • 25.Baggott C, Dodd M, Kennedy C, et al. Changes in children’s reports of symptom occurrence and severity during a course of myelosuppressive chemotherapy. J Ped Oncol Nurs 2010;27:307–315. doi: 10.1177/1043454210377619 [DOI] [PubMed] [Google Scholar]
  • 26.Hockenberry MJ, Hooke MC, Rodgers C, et al. Symptom trajectories in children receiving treatment for leukemia: A latent class growth analysis with multitrajectory modeling. J Pain Symptom Manage 2017;54:1–8. doi: 10.1016/j.jpainsymman.2017.03.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Hughes RE, Holland LR, Zanino D, et al. Prevalence and intensity of pain and other physical and psychological symptoms in adolescents and young adults diagnosed with cancer on referral to a palliative care service. J Adoles Young Adult Oncol, 2015;4:70–75. [DOI] [PubMed] [Google Scholar]
  • 28.Miller E, Jacob E, Hockenberry MJ. Nausea, pain, fatigue, and multiple symptoms in hospitalized children with cancer. Oncol Nurs Forum 2011;38:E382–393. [DOI] [PubMed] [Google Scholar]
  • 29.Rodgers C, Hooke MC, Ward J, Linder LA. Symptom clusters in children and adolescents with cancer. Semin Oncol Nurs, 2016;32:394–404. [DOI] [PubMed] [Google Scholar]
  • 30.Badger TA, Segrin C, Meek P (2011) Development and validation of an instrument for rapidly assessing symptoms: the general symptom distress scale. J Pain Symptom Manage 41(3):535–548 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Collins JJ, Byrnes ME, Dunkel IJ, Lapin J, Nadel T, Thaler HT, et al. The measurement of symptoms in children with cancer. J Pain Symptom Manag [Internet]. 2000/06/28 2000;19(5):363–77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10869877 [DOI] [PubMed] [Google Scholar]
  • 32.Simone CB II, Vapiwala V, Hampshire MK, Metz JM. Cancer patient attitudes towards analgesic utilization and pain intervention. Clin J Pain 2012;28:157–162. 10.1097/AJP.0b013e318223be30 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Luthy C, Cedraschi C, Pugliesi A, et al. Patients’ views about causes and preferences for the management of cancer-related fatigue—a case for non-congruence with the physicians. Support Care Cancer. 2011;19:363–70. 10.1007/s00520-010-0826-9 [DOI] [PubMed] [Google Scholar]
  • 34.Linder LA, Wu YP, Macpherson CF, et al. Oral medication adherence among adolescents and young adults with cancer prior to and following use of a smartphone-based medication reminder app. J Adoles Young Adult Oncol, epub ahead of print October 10, 2018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Linder LA, Erickson JM, Stegenga K, et al. Symptom self-management strategies reported by adolescents and young adults with cancer receiving chemotherapy. Support Care Cancer 2017;25:3793–3806. doi: 10.1007/s00520-017-3811-8 [DOI] [PubMed] [Google Scholar]
  • 36.Vetesse E, Cook S, Soman D, et al. Longitudinal evaluation of Supportive care Prioritization, Assessment and Recommendations for Kids (SPARK), a symptom screening and management application. BMC Cancer 2019;19:458. doi: 10.1186/s12885-019-5662-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ullrich CK, Dussel V, Orellana L, et al. Self-reported fatigue in children with advanced cancer: Results of the PediQUEST study. Cancer 2018;124:3776–3783. doi: 10.1002/cncr.31639 [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES